Registry of Patients With Plasma Cell Disorders
The goal of this observational study is to register patients with plasma cell disorders. The main questions it aims to answer are:

The incidence of plasma cell disorders both before and after malignancy
Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM)
Progression free survival (PFS)
overall survival
factors influencing overall survival, progression-free survival, and time to progression
Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients.
genetic characteristics of plasma cell disorder
cost-effectiveness of treatment in Thailand Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.
- EligibilityCriteria: Inclusion Criteria:  Both existing and newly diagnosed patients with plasma cell disorders, including monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, POEMS, light chain amyloidosis, solitary plasmacytoma, and multiple myeloma, according to the diagnostic criteria of the International Myeloma Working Group 2014 Aged 18 years and above  Exclusion Criteria:  insufficient data needed for analysis - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: plasma cell disorder patients - SamplingMethod: Non-Probability Sample